Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. (China)

Homepage: innogenpharm.com

Alternate names: Innogen Pharmaceutical Technology Co., Ltd., Shanghai Innogen Pharmaceutical Technology Co., Ltd., Shanghai Yinnuo Pharmaceutical Technology, Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., Shanghai Yinuo Pharmaceutical Technology Co., Ltd.

ROR: 005m5nx18

OpenAlex ID: I4405266879

Anti-Inflammatory Role of the Klotho Protein and Relevance to Aging

2024 · Gérald J. Prud'homme, Qinghua Wang · Cells · 82

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis

2025 · Yahao Wang, Yue Zhou, et al. · The Journal of Clinical Endocrinology & Metabolism · 54

Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice

2017 · Yun Wan, Xi Bao, et al. · Frontiers in Physiology · 34

Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes

2025 · Yan-Ru Lou, Yu-Long Xu, et al. · Clinical Pharmacokinetics · 18

Irisin alleviates hepatic steatosis by activating the autophagic SIRT3 pathway

2025 · Ying Zhao, Jia Li, et al. · Chinese Medical Journal · 16

Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study

2025 · Qinghua Wang, Qiaoli Cui, et al. · Diabetes Obesity and Metabolism · 12

Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial

2025 · Dalong Zhu, Jianhua Ma, et al. · Diabetologia · 8

Long-acting management of diabetes and associated complications using an injectable thermosensitive hydrogel incorporating IgG-conjugated GLP-1RA

2025 · Hancheng Wang, Zhiyong Chen, et al. · Theranostics · 8

Irisin Alleviates Impaired Mitochondrial Fusion via Enhancing PKA/SIRT3/mTOR Pathway in Hepatic Steatosis

2025 · Jia Li, Ying Zhao, et al. · Journal of Gastroenterology and Hepatology · 7

Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin

2025 · Qinghua Wang, Fan Jiang, et al. · Clinical Pharmacokinetics · 5

Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial

2026 · Fei Gao, Mingxia Yuan, et al. · Diabetes Obesity and Metabolism · 4

Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants

2025 · Xiaojie Wu, Jinjie He, et al. · Clinical Pharmacokinetics · 4

Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus

2025 · Qinghua Wang, Fan Jiang, et al. · Clinical Pharmacokinetics · 3

Supaglutide alleviates hepatic steatosis in monkeys with spontaneous MASH

2024 · Qinghua Wang, Yue Zhou, et al. · Diabetology & Metabolic Syndrome · 3

Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2)

2026 · Weiping Jia, Fei Gao, et al. · Nature Communications · 2

Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features

2026 · Yahao Wang, Zhihong Wang, et al. · Diabetes Obesity and Metabolism · 1

Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment

2026 · Rui Sun, Kun Wang, et al. · Advances in Therapy · 1

Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial

2025 · Rui Sun, Ying Wang, et al. · Diabetes Obesity and Metabolism · 1

Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation

2025 · Weiping Jia, Fan Jiang, et al. · Diabetes Obesity and Metabolism · 1

Efsubaglutide Alfa: A Comprehensive Pharmacological Review

2026 · Haolin Zheng, Run Yan, et al. · Clinical Pharmacokinetics

40-week repeat-dose toxicity, toxicokinetics, and immunogenicity of efsubaglutide alfa following subcutaneous administration in cynomolgus monkeys

2026 · Yahao Wang, Yuyang Lei, et al. · Regulatory Toxicology and Pharmacology

Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial

2026 · Dalong Zhu, Jianhua Ma, et al. · Diabetologia

Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)

2026 · Weiping Jia, Qinghua Wang · Diabetes Obesity and Metabolism

Works count: 23

Citation count: 521